KAZIA RAISES A$4.5 MILLION TO PROGRESS R&D PROGRAMS

SYDNEY, Jan. 16, 2023 /PRNewswire/ — Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce a placement of KZA shares, to institutional and sophisticated investors in Australia, at a price of A$0.11 per share. The…

No Comments

No comments yet.

Sorry, the comment form is closed at this time.